Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 3/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966606 | 0.82 | SMN1; SMN2 (0.49) | ALDH1A1HSD17B10MAPTHTTLMNA | |
| SCHEMBL8211026 | 0.79 | ALDH1A1 (0.57) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL1979959 | 0.79 | ALDH1A1 (0.57) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL20375229 | 0.78 | GRM4 (0.44) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL11957644 | 0.78 | GRM4 (0.44) | ALDH1A1MAPTHTTLMNAL3MBTL1 | |
| SCHEMBL28191370 | 0.78 | ALDH1A1 (0.51) | ALDH1A1TSHRMAPTLMNASMN1; SMN2 | |
| SCHEMBL13393646 | 0.77 | ALDH1A1 (0.44) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL14036718 | 0.77 | ALDH1A1 (0.55) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| Hydrochloric Acid SCHEMBL11087037 | 0.77 | ALDH1A1 (0.57) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL30236 | 0.77 | ALDH1A1 (0.55) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868723-B2 | Mutant-selective EGFR inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-01-16 | — | — | US | disclosed |
| US-9868723-B2 | Mutant-selective EGFR inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-01-16 | — | — | US | disclosed |
| EP-2637502-B1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2018-01-10 | — | — | EP | disclosed |
| US-20160332994-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-17 | — | — | US | disclosed |
| US-20160332994-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-17 | — | — | US | disclosed |
| US-9409887-B2 | Mutant-selective EGFR inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409887-B2 | Mutant-selective EGFR inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150025055-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-20150025055-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-8796255-B2 | Mutant-selective EGFR inhibitors and uses thereof | Celgene Avilomics Research, Inc (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796255-B2 | Mutant-selective EGFR inhibitors and uses thereof | Celgene Avilomics Research, Inc (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120157426-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157426-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012064706-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-7371753-B2 | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-13 | — | — | US | disclosed |
| US-7371753-B2 | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332994-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | EGFR, ERBB3, ERBB2 | ALDH1A1 4129/4885CYP3A4 4262/4885TDP1 3358/4885 |
| US-20150025055-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | EGFR, ERBB3, ERBB2 | ALDH1A1 4129/4885CYP3A4 4262/4885TDP1 3358/4885 |
| US-20120157426-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | EGFR, ERBB3, ERBB2 | ALDH1A1 4129/4885CYP3A4 4262/4885TDP1 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.